This product is a metabolite of bromhexine in the body. It has the characteristics of promoting the removal of viscous sputum and dissolving secretions. It can promote the removal of viscous secretions in the respiratory tract and reduce the retention of mucus, thus significantly promoting expectoration and improving respiratory conditions. When this product is used for treatment, the patient's mucus secretion can be restored to normal, and the amount of cough and sputum is usually significantly reduced. The surfactant on the respiratory mucosa can thus play its normal protective function. The toxicity index of ambroxol hydrochloride in acute toxicity tests is very low. The Ames test and micronucleus test show that ambroxol hydrochloride is not mutagenic. The carcinogenicity studies on mice and rats show that ambroxol hydrochloride is not carcinogenic.

The toxicity index of ambroxol in acute toxicity tests is very low. Ambroxol is not mutagenic (Ames and micronucleus tests). Carcinogenicity studies in mice and rats show that ambroxol is not carcinogenic.

This product is a third-generation quinolone broad-spectrum antibacterial drug, and its mechanism of action is to inhibit bacterial DNA helicase. This product has antibacterial activity against Gram-negative bacteria, Gram-positive bacteria and some anaerobic bacteria. There is no cross-resistance between this product and other types of antibacterial drugs. This product has high antibacterial activity against Enterobacteriaceae such as Escherichia coli, Shigella, Klebsiella, Proteus, Enterobacter, etc.; influenza bacillus, gonococci, etc. are also highly sensitive to this product; it also has certain antibacterial effects on Pseudomonas such as Acinetobacter and Pseudomonas aeruginosa, Staphylococcus, pneumococcus, hemolytic streptococci, etc.

This product is a mucolytic agent that can increase the secretion of serous glands in the respiratory mucosa and reduce the secretion of mucous glands, thereby reducing sputum viscosity; it can also promote the secretion of pulmonary surfactant, increase bronchial ciliary movement, and make sputum easier to cough up.

This product is a third-generation quinolone broad-spectrum antibacterial drug, and its mechanism of action is to inhibit bacterial DNA helicase. This product has antibacterial activity against Gram-negative bacteria, Gram-positive bacteria and some anaerobic bacteria. There is no cross-resistance between this product and other types of antibacterial drugs. This product has high antibacterial activity against Enterobacteriaceae such as Escherichia coli, Shigella, Klebsiella, Proteus, Enterobacter, etc.; influenza bacillus, gonococci, etc. are also highly sensitive to this product; it also has certain antibacterial effects on Pseudomonas such as Acinetobacter and Pseudomonas aeruginosa, Staphylococcus, pneumococcus, hemolytic streptococci, etc.